Draft Guidance Suggests Updated Tool for Assessing Suicidal Thoughts, Behavior in Trials

Drug Industry Daily
Drugmakers should use an updated instrument for the prospective assessment of suicidal thoughts and behaviors during clinical trials and follow new FDA advice on which trials and patients need such assessments, according to a new draft guidance.

To View This Article:


Subscribe To Drug Industry Daily